Ladarixin

Generic Name: Ladarixin

Drug Type: Small Molecule

Chemical Formula: C_₁₁H_₁₂F_₃NO_₆S_₂

CAS Number: 849776-05-2

Unique Ingredient Identifier: DEH7Q6472O

Background: Ladarixin is under investigation in clinical trial NCT04628481 (A Study of Oral Ladarixin in New-onset Type 1 Diabetes and a Low Residual Β-Cell Function).

Clinical Trials

Ladarixin With Sotorasib in Advanced NSCLC - Phase II

Phase 2

Withdrawn

Conditions: Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

Interventions: Drug: Sotorasib
Drug: Ladarixin

First Posted Date: 2023-04-18

Last Posted Date: 2024-03-29

Lead Sponsor: NYU Langone Health

Registration Number: NCT05815186

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States

Ladarixin With Sotorasib in Advanced NSCLC

Phase 1

Recruiting

Conditions: Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

Interventions: Drug: Sotorasib
Drug: Ladarixin

First Posted Date: 2023-04-18

Last Posted Date: 2025-02-19

Lead Sponsor: NYU Langone Health

Target Recruit Count: 40

Registration Number: NCT05815173

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States

Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes.

Phase 2

Terminated

Conditions: Type 1 Diabetes

Interventions: Drug: Ladarixin
Other: Placebo

First Posted Date: 2022-05-10

Last Posted Date: 2025-02-03

Lead Sponsor: Dompé Farmaceutici S.p.A

Target Recruit Count: 3

Registration Number: NCT05368402

Locations: 🇮🇹
Ospedale F. Spaziani Frosinone, Frosinone, Italy
🇮🇹
Università Campus Bio-Medico di Roma (UCBM) Policlinico Universitario, Rome, Italy

Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes

Phase 2

Withdrawn

Conditions: Type I Diabetes

Interventions: Drug: Ladarixin
Other: Placebo

First Posted Date: 2021-09-05

Last Posted Date: 2023-12-22

Lead Sponsor: Dompé Farmaceutici S.p.A

Registration Number: NCT05035368

Locations: 🇺🇸
Institute of Cellular Therapeutics Allegheny Health Network, Pittsburgh, Pennsylvania, United States

A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.

Phase 2

Terminated

Conditions: New-onset Type 1 Diabetes

Interventions: Drug: Ladarixin
Other: Placebo

First Posted Date: 2021-05-24

Last Posted Date: 2025-05-14

Lead Sponsor: Dompé Farmaceutici S.p.A

Target Recruit Count: 25

Registration Number: NCT04899271

Locations: 🇧🇪
Universitair Ziekenhuis Brussel (UZB), Jette, Belgium
🇺🇸
University of Colorado School of Medicine - Barbara Davis Center for Childhood Diabetes (BDC) - Specialty Clinic, Aurora, Colorado, United States
🇺🇸
Atlanta Diabetes Associates (ADA), Atlanta, Georgia, United States

and more 13 locations

A Single Dose Study About the Influence of Food on the Oral Bioavailability of Ladarixin Capsule in Healthy Volunteers

Phase 1

Completed

Conditions: no Condition

Interventions: Drug: Ladarixin

First Posted Date: 2021-04-22

Last Posted Date: 2024-01-17

Lead Sponsor: Dompé Farmaceutici S.p.A

Target Recruit Count: 36

Registration Number: NCT04854642

Locations: 🇨🇭
CROSS Research S.A., I Unit, Arzo, Canton Ticino, Switzerland

A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function

Phase 2

Active, not recruiting

Conditions: Recent Onset type1 Diabetes

Interventions: Drug: Placebo
Drug: Ladarixin

First Posted Date: 2020-11-13

Last Posted Date: 2024-11-07

Lead Sponsor: Dompé Farmaceutici S.p.A

Target Recruit Count: 140

Registration Number: NCT04628481

Locations: 🇺🇸
Atlanta Diabetes Associates (ADA), Atlanta, Georgia, United States
🇺🇸
UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇧🇪
Universitair Ziekenhuis Brussel (UZB), Jette, Belgium

and more 53 locations

A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus, Insulin-Dependent

Interventions: Drug: Ladarixin
Drug: Placebo

First Posted Date: 2016-06-28

Last Posted Date: 2024-04-19

Lead Sponsor: Dompé Farmaceutici S.p.A

Target Recruit Count: 76

Registration Number: NCT02814838

Locations: 🇩🇪
Med. Klinik und Poliklinik 3, Universitätsklinikum Giessen und Marburg GmbH, Giessen, Germany
🇧🇪
Universitair Ziekenhuis Brussel Diabetes Clinic, Brussels, Belgium
🇧🇪
Universitair Ziekenhuis Leuven Campus Gasthuisberg Endocrinology, Leuven, Belgium

and more 5 locations

Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid

Phase 2

Terminated

Conditions: Bullous Pemphigoid

Interventions: Drug: DF2156A

First Posted Date: 2012-04-05

Last Posted Date: 2023-12-22

Lead Sponsor: Dompé Farmaceutici S.p.A

Target Recruit Count: 4

Registration Number: NCT01571895

Locations: 🇩🇪
Klinik für Dermatologie, Allergologie und Venerologie - Universitätsklinikum Schleswig-Holstein, Campus Lübeck; Ratzeburger Allee 160, Lübeck, Germany
🇩🇪
Klinik für Dermatologie und Allergologie - Philips Universität; 35037, Marburg, Germany
🇮🇹
I Divisione di Dermatologia, Istituto Dermopatico dell'Immacolata, IRCCS;, Roma, Italy

and more 1 locations

Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

Phase 3

Completed

Conditions: ADHD

Interventions: Drug: LDX
Drug: Placebo

First Posted Date: 2008-06-16

Last Posted Date: 2021-06-09

Lead Sponsor: Shire

Target Recruit Count: 142

Registration Number: NCT00697515

Locations: 🇺🇸
University of CA, Irvine Child Development Center, Irvine, California, United States
🇺🇸
Vince & Associates Clinical Research, Overland Park, Kansas, United States
🇺🇸
Clinical Study Centers, LLC, Little Rock, Arkansas, United States

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy